Paroxetine

Selected References:

- Alwan S, et al. 2007. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 356(26):2684-2692.
- Alwan S, Friedman JM, Chambers C: 2016. Safety of selective serotonin reuptake inhibitors in pregnancy: a review of current evidence. CNS Drugs 30(6):499-515.
- Andrade S, et al. 2009. Antidepressant use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 18(3):246-252.
- Bakker MK, et al. 2010. First-trimester use of paroxetine and congenital heart defects: a population-based case-control study. Birth Defects Res A Clin Mol Teratol 88(2):94-100.
- Berard A, et al. 2016. The risk of major cardiac malformations associated with paroxetine use during the first trimester of pregnancy: A systematic review and meta-analysis. Br J Clin Pharmacol; 81(4):589-604.
- Berard A, et al. 2017. Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: An updated analysis of the Quebec Pregnancy Cohort. BMJ Open;7:e013372.
- Biffi, A, et al. 2020. Use of antidepressants during pregnancy and neonatal outcomes: An umbrella review of meta-analyses of observational studies. Journal of Psychiatric Research, 124:99–108.
- Bonari L, et al. 2004. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry 49(11):726-735.
- Chambers C, et al. 2006. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 354(6)579-587.
- Costei A, et. al. 2002. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 156:1129-1132.
- Creeley, C. E., & Denton, L. K. 2019. Use of Prescribed Psychotropics during Pregnancy: A Systematic Review of Pregnancy, Neonatal, and Childhood Outcomes. Brain Sciences, 9(9)::235
- Den Besten-Bertholee D, et al. 2024. Sertraline, citalopram and paroxetine in lactation: passage into breastmilk and infant exposure. Front Pharmacol.15:1414677.
- Desaunay P, et al. 2023. Benefits and Risks of Antidepressant Drugs During Pregnancy: A Systematic Review of Meta-analyses. Paediatr Drugs. 25(3):247-265.
- De Vries, C., et al. 2020. A Systematic Review and Meta-Analysis Considering the Risk for Congenital Heart Defects of Antidepressant Classes and Individual Antidepressants. Drug Safety. https://doi.org/10.1007/s40264-020-01027
- Diav-Citrin O, et al. 2008. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled observational study. Br J Clin Pharmacol 66(5): 695-705.
- Einarson A, et al. 2008. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry AiA:1-5.
- Einarson A, et al. 2009. Rates of spontaneous and therapeutic abortions following use of antidepressants in pregnancy: results from a large prospective database. J Obstet Gynaecol Can 31:452-456.
- Fischer Fumeaux, CJ, et al. 2019. Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence – an update. Expert Opinion on Drug Safety, 18(10):949–963.
- Fitton, CA, et al. 2020. In utero exposure to antidepressant medication and neonatal and child outcomes: a systematic review. Acta Psychiatrica Scandinavica, 141(1): 21–33.
- Gabriel M & Sharma V. 2017. Antidepressant discontinuation syndrome. CMAJ;189:E747.
- Galbally, M., et al. 2020. Antidepressant exposure in pregnancy and child sensorimotor and visuospatial development. Journal of Psychiatric Research;S0022-3956(20)31095-5.

- Gao S, et al. 2018. Selective serotonin reuptake inhibitor use during early pregnancy and congenital malformations: a systematic review and meta-analysis of cohort studies of more than 9 million births. BMC Med. 16:205.
- Grigoriadis S et al. 2013. Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systematic review and meta-analysis of the best evidence.J Clin Psychiatry. 74(4):e293-308.
- Hansen CH, et al. 2017. The six most widely used selective serotonin reuptake inhibitors decrease androgens and increase estrogens in the H295R cell line. Toxicol In Vitro. 41:1-11
- Hendrick V, et al. 2001. Use of sertraline, paroxetine and fluvoxamine by nursing women. Br J Psychiatry 179:163-166
- Hernandez-Diaz S. 2007. Risk factors for persistent pulmonary hypertension of the newborn. Pediatrics 120 (2):e272-282.
- Jordan S, et al. 2016. Selective serotonin reuptake inhibitor (SSRI) in pregnancy and congenital anomalies: Analysis of linked databases in Wales, Norway and Funen, Denmark. PLOS One; 11(12): e0165122.
- Kallen B, et al. 2008. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 17(8):801-806.
- Kieviet N, et al. 2015. Risk factors for poor neonatal adaptation after exposure to antidepressants in utero. Acta Paediatr.104(4):384-91.
- Lebin LG, Novick AM. 2022. Selective Serotonin Reuptake Inhibitors (SSRIs) in Pregnancy: An Updated Review on Risks to Mother, Fetus, and Child. Curr Psychiatry Rep: 24, 687–695.
- Leerssen, E. C. M., et al. 2019. Severe transient neonatal long QT syndrome due to maternal paroxetine usage: a case report. Cardiology in the Young, 29(10), 1300–1301. https://doi.org/10.1017/S1047951119001938
- Levinson-Castiel R, et al. 2006. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 160:173-176.
- Louik C, et al. 2007. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 356(26):2675-2683.
- McDonagh MS, et al. 2014. Antidepressant treatment of depression during pregnancy and the postpartum period. Evidence report/technology assessment No. 216. (Prepared by the Pacific Northwest Evidnece-based Practice Center under Contract No. 290-2007-10057-I.). Rockville, MD: Agency for Healthcare Research and Quality.
- Mesches, G. A., et al. 2020. A common clinical conundrum: Antidepressant treatment of depression in pregnant women. Seminars in Perinatology, 44(3), 151229. https://doi.org/10.1016/j.semperi.2020.151229
- Misri S, et al. 2000. Paroxetine levels in postpartum depressed women, breastmilk, and infant serum. J Clin Psychiatry 61(11):828-832.
- Molenaar, N. M., et al. 2018. Guidelines on treatment of perinatal depression with antidepressants: An international review. The Australian and New Zealand Journal of Psychiatry, 52(4), 320–327.
- Myles N, et al. 2013. Systematic meta-analysis of individual selective serotonin reuptake inhibitor medications and congenital malformations. Aust N Z J Psychiatry.47(11):1002-12.
- Nakhai-Pour HR, et al. 2010. Use of antidepressants during pregnancy and the risk of spontaneous abortion. CMAJ 182(10):1031-1037.
- Nulman I, et al. 1997. Neurodevelopment of children exposed in utero to antidepressant drugs. NEJM 336(4):258-262.
- Nulman I, et al. 2012.Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression. Am J Psychiatry. 2012 169(11):1165-1174.
- Ornoy, A., & Koren, G. 2018. Selective serotonin reuptake inhibitor use in pregnant women; pharmacogenetics, drug-drug interactions and adverse effects. Expert Opinion on Drug Metabolism & Toxicology, 14(3), 247–259. https://doi.org/10.1080/17425255.2018.1430139
- Ornoy A, Koren G. 2014. Selective serotonin reuptake inhibitors in human pregnancy: On the way to resolving the controversy. Semin Fetal Neonatal Med. 19(3):188-194.
- Orsolini L, Bellantuono C. 2015. Serotonin reuptake inhibitors and breastfeeding: A systematic review. Hum Psychopharmacol. 30:4-20.

- Paxil Prescribing Information, 020936s047lbl.pdf. (n.d.). Retrieved January 7, 2021, from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020936s047lbl.pdf
- Pogliani L, Baldelli S, Cattaneo D et al. Selective serotonin reuptake inhibitors passage into human milk of lactating women. J Matern Fetal Neonatal Med. 2018;1-11.
- Prady, S. L., et al. 2018. A systematic review of maternal antidepressant use in pregnancy and short- and long-term offspring's outcomes. Archives of Women's Mental Health, 21(2), 127–140.
- Raffi, E. R., et al. 2019. Safety of Psychotropic Medications During Pregnancy. Clinics in Perinatology, 46(2), 215–234.
- Sanz E, et al. 2005. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 365:482-487.
- Schoretsanitis G, et al. 2020. The impact of pregnancy on the pharmacokinetics of antidepressants: a systematic critical review and meta-analysis. Expert Opin Drug Metab Toxicol.16(5):431-440.
- Stowe Z, et al. 2000. Paroxetine in human breastmilk and nursing infants. Am J Psychiatry 157(2):185-189.
- Tanrikut, C., et al. 2010. Adverse effect of paroxetine on sperm. Fertility and Sterility, 94(3), 1021–1026.
- Tosounidou, S., & Gordon, C. 2020. Medications in pregnancy and breastfeeding. Best Practice & Research. Clinical Obstetrics & Gynaecology, 64, 68–76.
- Trifu, S. C., et al. 2020. Affective disorders: A question of continuing treatment during pregnancy (Review). Experimental and Therapeutic Medicine, 20(4), 3474–3482.
- Uguz, F. 2020. Selective serotonin reuptake inhibitors and the risk of congenital anomalies: a systematic review of current meta-analyses. Expert Opinion on Drug Safety, 19(12), 1595–1604.
- Uguz F, Arpaci N. 2016. Short-Term Safety of Paroxetine and Sertraline in Breastfed Infants: A Retrospective Cohort Study from a University Hospital. Breastfeed Med.11:487-9.
- Uguz F. 2019. Short-term safety of paroxetine plus low-dose mirtazapine during lactation. Breastfeed Med. 14(2):131-132.
- Wang S, et al. 2015. Selective Serotonin Reuptake Inhibitors (SSRIs) and the Risk of Congenital Heart Defects: A Meta-Analysis of Prospective Cohort Studies. Journal of the American Heart Association. 4(5).
- Weissman AM, et al. 2004. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. Am J Psychiatry June; 161(6): 1066- 1078.
- Wichman CL, et al. 2009. Congenital heart diease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo CLin Proc 84(1):23- 27.
- Wurst K, et al. 2010. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol 88(3):159-170
- Yardimci, A., et al. 2019. Effects of long-term paroxetine or bupropion treatment on puberty onset, reproductive and feeding parameters in adolescent male rats. Andrologia, 51(6), e13268.
- Zheng L, Yang H, Dallmann A. 2022. Antidepressants and Antipsychotics in Human Pregnancy: Transfer Across the Placenta and Opportunities for Modeling Studies. J Clin Pharmacol. 62 Suppl 1:S115-S128.

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de abril de 2025.

Paroxetine

Selected References:

- Barr DB, et al. 2010. Pesticide concentrations in maternal and umbilical cord sera and their relation to birth outcomes in a population of pregnant women and newborns in New Jersey. Sci Total Environ, 408(4):790-795.
- Centers for Disease Control and Prevention. 2022. Prevent Mosquito Bites. Available at URL: https://www.cdc.gov/zika/prevention/prevent-mosquito-bites.html.
- Hall JG, et al. 1975. Coarctation of the aorta in male cousins with similar maternal environmental exposure to insect repellant and insecticides. Pediatrics 55:425-427.
- Koren G, et al. 2003. DEET-based insect repellents: safety implications for children and pregnant and lactating women. CMAJ, 169(3):209-212.
- Kuhlmann RS, et al. 1981. N,N-diethyl-meta-toluamide: embryonic sensitivity. Teratology, 23:48a.
- McGready R, et al. 2001. Safety of the insect repellant N,N-diethyl-m-toluamide (DEET) in pregnancy. Am J Trop Med Hyg, 65:285-289.
- Özokan G et al. 2024. Comparison of the cytotoxicity and zebrafish embryo toxicity of insect repellent ingredients: p-Methane-3, 8-diol synthesized by green chemistry from Eucalyptus citriodora and N, N-diethyl-meta-toluamide. Drug and Chemical Toxicology, 47(6): 1193-1294.
- Schaefer C and Peters PW. 1992. Intrauterine diethyltoluamide exposure and fetal outcome. Reprod Toxicol, 6:175-176.
- Schoenig GP, et al. 1994. Teratologic evaluations of N,N-diethyl-m-toluamide (DEET) in rats and rabbits. Fundam Appl Toxicol, 23:63-69.
- Segal TR, et al. 2017. Urinary concentrations of 3-(diethylcarbamoyl)benzoic acid (DCBA), a major metabolite of N,N-diethyl-m-toluamide (DEET) and semen parameters among men attending a fertility center. Hum Reprod, 32(12): 2532-2539.
- Selim S, et al. 1995. Absorption and metabolism of DEET following dermal application to human volunteers. Fundam Appl Toxicol, 25:95-100.
- Snodgrass RL, et al. 1982. Dermal penetration and potential for placental transfer of the insect repellant, N,N-diethyl-m-toluamide. Am Ind Hyg Assoc J, 43:747-753.
- Sudakin DL, Trevathan WR. 2003. DEET: a review and update of safety and risk in the general population. J Toxicol Clin Toxicol. 41(6):831-9.
- United States Environmental Protection Agency (EPA). 2022. DEET. Available at URL: https://www.epa.gov/insect-repellents/deet.
- Wickerham EL, et al. 2012. Reduced birth weight in relation to pesticide mixtures detected in cord blood of full-term infants. Environmental International, 47:80-85.
- Wright DM, et al. 1992. Reproductive and developmental toxicity of N,N-diethyl-m-toluamide in rats. Fundam Appl Toxicol, 19:33-42.

- Wylie BJ, et al. 2016. Insect repellants during pregnancy in the era of the Zika virus. Obstet Gynecol, 128(5):1111-1115.

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de abril de 2025.

Paroxetine

Selected References:

- American College of Obstetricians and Gynecologists. 2013. ACOG committee opinion no. 558: Integrating immunizations into practice. Obstet Gynecol 121(4):897-903.
- Angelo MG, et al. 2014. Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme. Pharmacoepidemiol Drug Saf. 23(5):466-79.
- Baril L, et al. 2015. Risk of spontaneous abortion and other pregnancy outcomes in 15-25 year old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom. Vaccine 33(48):6884-91.
- Bukowinski AT, et al. 2020. Maternal and infant outcomes following exposure to quadrivalent human papillomavirus vaccine during pregnancy. Vaccine. 18;38(37):5933-5939.
- Centers for Disease Control and Prevention. 2025. Human Papillomavirus (HPV) Vaccine Safety. Available at https://www.cdc.gov/vaccine-safety/vaccines/hpv.html
- Chen W, et al. 2019. Safety of a quadrivalent human papillomavirus vaccine in a Phase 3, randomized, double-blind, placebo-controlled clinical trial among Chinese women during 90 months of follow-up. Vaccine 37(6):889-97.
- Dousti R, Allahqoli L, Ayar Kocaturk A, Hakimi S. 2023. Can human papillomavirus vaccination during pregnancy result in miscarriage and stillbirth? A meta-analysis and systematic review. Eur J Midwifery. 2023;7:9.
- Faber MT, et al 2019. Adverse pregnancy outcomes and infant mortality after quadrivalent HPV vaccination during pregnancy. Vaccine 37(2)265-271.

- Garland SM, et al. 2009. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol 114(6):1179-1188.
- Garolla A et. Al. 2013. Sperm viral infection and male infertility: focus on HBV, HCV, HIV, HPV, HSV, HCMV, and AAV. J Reprod Immunol 100(1):20-9.
- Goss MA, et al. 2015. Final report on exposure during pregnancy from a pregnancy registry for quadrivalent human papillomavirus vaccine. Vaccine 33(29): 3422-3428.
- Forbes N, Montroy J, Salvadori MI, Dubey V. 2024. Summary of the National Advisory Committee on Immunization (NACI) Statement: Updated guidance on human papillomavirus (HPV) vaccines. Can Commun Dis Rep. 50(12):419-425.
- Kharbanda EO, et al. 2018. Risk of spontaneous abortion after inadvertent human papillomavirus vaccination in pregnancy. Obstet Gynecol 132:34-44.
- Kharbanda EO, et al. 2021. Association of Inadvertent 9-Valent Human Papillomavirus Vaccine in Pregnancy With Spontaneous Abortion and Adverse Birth Outcomes. JAMA Netw Open 4(4): e214340.
- Landazabal CS, et al. 2019. Safety of 9- valent human papillomavirus vaccine administration among pregnant women: Adverse event reports in the Vaccine Adverse Event Reporting System (VAERS), 2014-2017. Vaccine 37:1229-1234.
- Lawton B, et al. 2018. Association of prior HPV vaccinations with reduced preterm birth: a population based study. Vaccine 36: 134-140.
- Lipkind HS, et al. 2017. Maternal and infant outcomes after human papillomavirus vaccination in the periconceptional period or during pregnancy. Obstet Gynecol; 130(3):599-608.
- Mammas IN, et al. 2011. Can 'high-risk' human papillomaviruses (HPVs) be detected in human breast milk? Acta Paediatr 100(5):705-7.
- Markowitz LE, et al. 2007. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56 (RR-2):1-24.
- Matys K, et al. 2012. Mother-infant transfer of anti-human papillomavirus (HPV) antibodies following vaccination with the quadrivalent HPV (type 6/11/16/18) virus-like particle vaccine. Clin Vaccine Immunol Jun; 19(6):881-5.
- McDonnold M, et al. 2014. High risk human papillomavirus at entry to prenatal care and risk of preeclampsia. Am J Obstet Gynecol 210(2):138.e1-5.
- Moreira ED, E et al. 2016. Safety profile of the 9-valent HPV vaccine: A combined analysis of 7 phase III clinical trials. Pediatrics. 138(2):e20154387.
- Muscianisi F, Foresta C, Garolla A. Role of HPV vaccination for prevention of male infertility. Minerva Endocrinol (Torino). 2022 Mar;47(1):70-76.
- Panagiotou OA, et al. 2015. Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial. BMJ 7; 351:h4358.
- Segal L, et al. 2011. Evaluation of the intramuscular administration of Cervarix vaccine on fertility, pre- and post-natal development in rats. Reprod Toxicol 31(1):111-20.
- Scheller NM, et al. 2017. Quadrivalent HPV vaccination and the risk of adverse pregnancy outcomes. N Engl J Med 376:1223-1233.
- Wacholder S, et al. 2010. Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomized clinical trials. BMJ 340:C712.
- Wang A, et al. 2020. Pregnancy Outcomes After Human Papillomavirus Vaccination in Periconceptional Period or During Pregnancy: A Systematic Review and Meta-analysis. Hum Vaccin Immunother. 3;16(3):581-589.
- Wise LD, et al. 2008. Lack of effects on fertility and developmental toxicity of a quadrivalent HPV vaccine in Sprague-Dawley rats. Birth Defects Res (B) 83:561-572.
- Yan X, Li H, Song B, et al. 2023. Association of periconceptional or pregnancy exposure of HPV vaccination and adverse pregnancy outcomes: A systematic review and meta-analysis with trial sequential analysis. Front Pharmacol. 2023;14:1181919
- Zhang J, Lian Z, Xue X, et al. 2024. Does HPV vaccination during periconceptional or gestational period increase the risk of adverse pregnancy outcomes?-An updated systematic review and meta-analysis based on timing of

vaccination. Acta Obstet Gynecol Scand. 103(10):1943-1954.

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de abril de 2025.

Paroxetine

Selected References:

- Adane AA, et al. 2016. Diabetes in pregnancy and childhood cognitive development: a systematic review. Pediatrics,137(5):e20154234.
- American Diabetes Association. 2024. Management of diabetes in pregnancy: Standards of care in diabetes—2024. Diabetes Care. 47(Supplement_1):S282-S294.
- Bhattacharyya A, et al. 2001. Insulin lispro and regular insulin in pregnancy. QJM. 94(5):255-260.
- Bytoft B, et al. 2016. Long-term cognitive implications of intrauterine hyperglycemia in adolescent offspring of women with type 1 diabetes (the EPICOM Study). Diabetes Care, 39:1356-1363.
- Chehab RF, et al. 2022. Glycemic control trajectories and risk of perinatal complications among individuals with gestational diabetes. JAMA Netw Open, 5(9):e2233955.
- Chen K-R, et al. 2023. Childhood neurodevelopmental disorders and maternal diabetes: A population-based cohort study. Dev Med Child Neurol. 65:933–941.
- Coetzee EJ and Levitt NS. 2000. Maternal diabetes and neonatal outcome. Seminars in Neonatology. 5(3):221-229.
- Feleke BE, et al. 2022. Maternal and newborn effects of gestational diabetes mellitus: A prospective cohort study. Prim Care Diabetes, 16(1):89-95.
- Kinnunen J, et al. 2023 Gestational diabetes is associated with the risk of offspring’s congenital anomalies: a register-based cohort study. BMC Pregnancy Childbirth. 23(1):708.

- Landon MB. 2000. Obstetric management of pregnancies complicated by diabetes mellitus. Clinical Obstetrics and Gynecology, 43(1):65-74.
- Langer O, et al. 2000. A comparison of glyburide and insulin in women with gestational diabetes mellitus. New England Journal of Medicine, 343(16):1134-1138.
- Leth-Møller M, et al. 2024. Effect of gestational diabetes on fetal growth rate and later overweight in the offspring, Journal of Clinical Endocrinology & Metabolism. dgae428.
- Meek CL. 2023. An unwelcome inheritance: childhood obesity after diabetes in pregnancy. Diabetologia. 66:1961–1970.
- Nagasawa M, et al. 2024. Maternal diabetes and risk of offspring congenital heart diseases: the Japan Environment and Children's Study. Environ Health Prev Med. 29:23.
- National Institute of Child Health and Human Development. 2011. Managing Gestational Diabetes: A Patient's Guide to a Healthy Pregnancy. Available at: https://www.nichd.nih.gov/publications/product/211. [Accessed February 2023]
- Ornoy A. 2005. Growth and neurodevelopmental outcome of children born to mothers with pregestational and gestational diabetes. Pediatr Endocrinol Rev, 3(2):104–113.
- Papazoglou AS, et al. 2022. Maternal diabetes mellitus and its impact on the risk of delivering a child with congenital heart disease: a systematic review and meta-analysis. J Matern Fetal Neonata. Med, 35(25):7685-7694.
- Pectasides M and Kalva S. 2011. Diabetes revealed: multisystem danger. American Journal of Roentgenology, 196(2): 274-286.
- Preda A, et al. 2021. Analysis of maternal and neonatal complications in a group of patients with gestational diabetes mellitus. Medicina, 57(11):1170.
- Rizzo TA, et al. 1995. Prenatal and perinatal influences on long-term psychomotor development in offspring of diabetic mothers. Am J Obstet Gynecol, 173(6):1753-1758.
- Rosenn BM and Miodovnik M. 2000. Medical complications of diabetes mellitus in pregnancy. Clinical Obstetrics and Gynecology, 43(1):17-31.
- Santos JDC, et al. 2023. Diabetes among women with preterm births: outcomes of a Brazilian multicenter study. Einstein (Sao Paulo). 21:eAO0515.
- Sells CJ, et al. 1994. Long-term developmental follow-up of infants of diabetic mothers. J Pediatr, 125(1):S9-17.
- Serlin D and Last R. 2009. Diagnosis and management of gestational diabetes mellitus. American Family Physician, 80(1): 57-62.
- Sweeting A, et al. 2024. Relationship between early-pregnancy glycemia and adverse outcomes: findings from the TOBOGM study. Diabetes Care. 47(12): 2085–2092.

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de abril de 2025.

Paroxetine

Selected References:

- Adam DN, et al. 2023. Expert consensus on the systemic treatment of atopic dermatitis in special populations. J Eur Acad Dermatol Venereol. 37(6):1135-1148.
- Balakirski G, et al. 2022. Atopic dermatitis and pregnancy. J Allergy Clin Immunol. 149(4):1185-1194.
- Hamann CR, et al. 2019. Pregnancy complications, treatment characteristics and birth outcomes in women with atopic dermatitis in Denmark. J Eur Acad Dermatol Venereol. Mar;33(3):577-587.
- Horev, A., Shalom, G., Weintraub, A. Y., Freud, T., & Cohen, A. D. 2022. Atopic Dermatitis and Infertility: A Nationwide Retrospective Cohort Study. *Dermatology (Basel, Switzerland)*, *238*(2), 313–319.
- Kim J, et al. 2019. Pathophysiology of atopic dermatitis: Clinical implications. Allergy Asthma Proc. 40(2):84-92.
- Koutroulis I, et al. 2011. Atopic dermatitis in pregnancy: current status and challenges. Obstet Gynecol Surv. 66(10):654-663.
- Munera-Campos M, et al. 2024. Atopic Dermatitis: Fertility, Pregnancy, and Treatment Perspectives. Am J Clin Dermatol. 25(1):55-66.
- Napolitano M, et al. 2021. New emergent therapies for atopic dermatitis: A review of safety profile with respect to female fertility, pregnancy, and breastfeeding. Dermatol Ther. 34(1):e14475.
- Pfaller B, et al. 2020. Biologicals in atopic disease in pregnancy: an EAACI position paper. Allergy. 76(1):71-89.
- Ramos CL, et al. (2023). Monoclonal Antibodies (Biologics) for Allergic Rhinitis, Asthma, and Atopic Dermatitis During Pregnancy and Lactation. Immunol Allergy Clin North Am. 43(1):187-197.
- Schuler CF, et al. 2023. Novel insights into atopic dermatitis. Allergy Clin Immunol. 151(5):1145-1154.
- Silverberg J. I. 2018. Associations between atopic dermatitis and other disorders. *F1000Research*, *7*, 303.
- Sroka-Tomaszewska J, et al. 2021. Molecular Mechanisms of Atopic Dermatitis Pathogenesis. Int J Mol Sci. 22(8):4130.
- Torres T, et al. 2019. Update on Atopic Dermatitis. Acta Med Port. 32(9):606-613.
- Vaughan Jones SA, et al. 1999. A prospective study of 200 women with dermatoses of pregnancy correlating the clinical findings with hormonal and immunopathological profiles. Br J Dermatol. 141:71–81.
- Vestergaard C, et al. 2019. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. J Eur Acad Dermatol Venereol. 33(9):1644-1659
- Wollenberg A. et al.2022. European guideline (EuroGuiDerm) on atopic eczema – part II: non-systemic treatments and treatment recommendations for special AE patient populations. J Eur Acad Dermatol Venereol. 2022 Nov;36(11):1904-1926.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en MotherToBaby.org .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de abril de 2025.